Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06915792
PHASE4

PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy

Sponsor: University of California, Los Angeles

View on ClinicalTrials.gov

Summary

This randomized controlled trial compares two common medications, labetalol and extended-release nifedipine, to determine which is more effective at managing postpartum high blood pressure. We hypothesize that extended-release nifedipine will better control blood pressure and reduce the need for continued medication beyond six weeks postpartum. The study will enroll 110 postpartum participants, randomly assigning them to one of the two medications, with remote blood pressure monitoring to evaluate treatment effectiveness and inform postpartum hypertension management.

Official title: Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension

Key Details

Gender

FEMALE

Age Range

18 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

110

Start Date

2025-04-01

Completion Date

2025-10-31

Last Updated

2025-04-08

Healthy Volunteers

No

Interventions

DRUG

Labetalol

Labetalol is a beta-blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral labetalol will be initiated at 200mg twice or three times daily and adjusted up to 2400 mg/day as needed for blood pressure control.

DRUG

Nifedipine

Nifedipine is a calcium channel blocker commonly used to manage hypertension in pregnancy and postpartum. In this study, oral extended-release nifedipine will be initiated at 30mg once daily and adjusted up to 120mg/day as needed for blood pressure control.